Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy

Experimental and Clinical Psychopharmacology

Volumn 6, Issue 3, 1998, Pages 331-343

  Rose, Jed E ^a,b,c   Behm, Frederique M ^a,c   Westman, Eric C ^a,c  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; QUESTIONNAIRE; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TRANSDERMAL DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

EID: 0031855134     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.6.3.331     Document Type: Article

References (36)

1. Abacus Concepts. (1996). StatView reference. Berkeley, CA: Author.
2. Armstrong, M., Bakke, J., Conrad, L., Freis, E., Fremont, R., Kirkendall, W., Pilz, C., Ramirez, E., Richardson, D., & Jr., J. W. (1960). A double-blind control study of antihypertensive agents. Archives of Internal Medicine, 106, 81-96.
3. Benowitz, N. L., & Jacob, P. (1993). Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clinical Pharmacological Therapeutics, 53, 316-323.
4. Burling, T. A., Lovett, S. B., Richter, W. T., & Frederiksen, L. W. (1983). Alveolar carbon monoxide: The relative contributions of daily cigarette rate, cigarette brand, and smoking topography. Addictive Behaviors, 8, 23-26.
5. Clarke, P. B. S. (1991). Nicotinic receptor blockade therapy and smoking cessation. British Journal of Addiction, 86, 501-555.
6. Collett, D. (1994). Modelling survival data in medical research. London: Chapman & Hall.
7. Collins, A. C., Evans, C. B., Miner, L. L., & Marks, M. J. (1986). Mecamylamine blockade of nicotine responses: Evidence for two brain nicotinic receptors. Pharmacology and Biochemistry of Behavior, 24, 1767-1773.
8. Corrigall, W. A., & Coen, K. M. (1989). Nicotine maintains robust self-administration in rats on a limited-access schedule. Journal of Clinical Psychopharmacology, 99, 473-478.
9. Elmer, G. I., Pieper, J. O., Goldberg, S. R., & George, F. R. (1995). Opioid operant self-administration, analgesia, stimulation and respiratory depression in mu-deficient mice. Journal of Clinical Psychopharmacology, 117, 23-31.
10. Fiore, M. C., Bailey, W. C., & Cohen, S. J. (1996). Smoking cessation: Clinical Practice Guideline (AHCPR Publication No. 96-0692). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.
11. Foulds, J., Stapleton, J., Feyerabend, C., Vesey, C., Jarvis, M., & Russell, M. A. H. (1992). Effect of transdermal nicotine patches on cigarette smoking: A double blind crossover study. Journal of Clinical Psychopharmacology, 106, 421-427.
12. Glover, E. D. (1993). What can we expect from a transdermal patch? A theoretical/practical approach. Health Values, 17, 69-79.
13. Imperial Cancer Research Fund General Practice Research Group. (1993). Effectiveness of a nicotine patch in helping people stop smoking: Results of a randomised trial in general practice. British Medical Journal, 306, 1304-1308.
14. Jacob, P., Wilson, M., & Benowitz, N. (1981). Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. Journal of Chromatography, 222, 61-70.
15. Keppel, G. (1982). Design and analysis: A researcher's handbook (2nd ed.). Englewood Cliffs, NJ: Prentice-Hall.
16. Levin, E. D., & Rose, J. E. (1991). Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Brain Research Bulletin, 27, 125-128.
17. Levin, E. D., Westman, E. C., Stein, R. M., Carnahan, E., Sanchez, M., Herman, S., Behm, F., & Rose, J. E. (1993). Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates the rewarding effects of smoking. Journal of Clinical Psychopharmacology, 14, 41-49.
18. Martin, B. R., Onaivi, E. S., & Martin, T. J. (1989). What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochemistry and Pharmacology, 38, 3391-3397.
19. Maxwell, S. E., & Delaney, H. D. (1990). Designing experiments and analyzing data. Belmont, CA: Wadsworth.
20. Meyer, R. E. (1988). Conditioning phenomena and the problem of relapse in opioid addicts and alcoholics. In B. A. Ray (Ed.), Learning factors in substance abuse (pp. 161-179). Washington, DC: U.S. Department of Health and Human Services.
21. Palmer, K. J., Buckley, M. M., & Faulds, D. (1992). Transdermal nicotine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs, 44, 498-529.
22. Pomerleau, C. S., Pomerleau, O. F., & Majchrzak, M. J. (1987). Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology, 91, 391-393.
23. Rose, J. E., Behm, F. M., Westman, E. C., Levin, E. D., Stein, R. M., Lane, J. D., & Ripka, G. V. (1994a). Combined effects of nicotine and mecamylamine in attenuating smoking satisfaction. Experimental and Clinical Psychopharmacology, 2, 1-17.
24. Rose, J. E., Behm, F. M., Westman, E. C., Levin, E. D., Stein, R. M., & Ripka, G. V. (1994b). Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clinical and Pharmacological Therapeutics, 56, 86-99.
25. Rose, J. E., & Levin, E. O. (1991). Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacology and Biochemistry of Behavior, 41, 219-226.
26. Rose, J. E., Sampson, A., Levin, E. D., & Henningfield, J. E. (1989). Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacology and Biochemistry of Behavior, 32, 933-938.
27. Russell, M. A. H. (1991). The future of nicotine replacement. In R. West & N. E. Grunberg (Eds.), British Journal of Addiction (pp. 653-658). London: Carfax Publishing.
28. Russell, M. A. H., Stapleton, J. A., Feyerabend, C., Wiseman, S. M., Gustavsson, G., Sawe, U., & Connor, P. (1993). Targeting heavy smokers in general practice: Randomised controlled trial of transdermal nicotine patches. British Medical Journal, 306, 1308-1312.
29. Sheskin, D. J. (1997). Handbook of parametric and nonparametric statistical procedures. Boca Raton, FL: CRC Press.
30. Shiffman, S. M., & Jarvik, M. E. (1976). Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology, 50, 35-39.
31. Shipley, R., & Rose, J. (1992). Quit smart: Stop smoking with the nicotine skin patch and other new methods. Durham, NC: JB Press.
32. Stolerman, I. P. (1986). Could nicotine antagonists be used in smoking cessation? British Journal of Addiction, 81, 47-53.
33. Tennant, J., F. S., Tarver, A. L., & Rawson, R. A. (1984). Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. NIDA Research Monographs, 49, 239-246.
34. Westman, E. C., Levin, E. D., & Rose, J. E. (1992). Smoking while wearing the nicotine patch: Is smoking satisfying or harmful? Clinical Research, 40, 871A. (Abstract)
35. Westman, E. C., Levin, E. D., & Rose, J. E. (1993). The nicotine patch in smoking cessation: A randomized trial with telephone counseling. Archives of Internal Medicine, 153, 1917-1923.
36. Wilson, M. C., & Schuster, C. R. (1972). The effects of chlorpromazine on psychomotor stimulant self-administration in the rhesus monkey. Psychopharmacologia, 26, 115-126.